Cryoport Q3 revenue flat YoY at $56.7M; services up 9%, product down 14%

Cryoport, Inc.

2024-Q3 EPS reported -$2.07 revenue$168,853,000

Net loss attributable to common stockholders: $1.2M ($0.02/share) vs $15.3M loss ($0.31) YoY.
Life Sciences Services revenue up 9% to $39.3M; gross margin improved to 46%.
Life Sciences Products revenue down 14% to $17.4M; total gross margin 44.8%.
Full-year 2024 revenue guidance reaffirmed at $225-235M; management targets positive adjusted EBITDA in 2025.
Repurchased $175M principal of 2026 convertible notes for $154.5M; cash and short-term investments $272.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.